Grünenthal GmbH, an international research based pharmaceutical company, has signed a global license agreement with BioClinica, a global provider of clinical trial management solutions, to use BioClinica OnPoint CTMS in support of Grünenthal’s ongoing clinical trials. Grünenthal concluded that OnPoint could deliver on their stated requirements faster and more cost effectively, and liked the fact that OnPoint could integrate with other clinical systems. OnPoint also allows clinical staff to do much of their work within Microsoft Office applications, a familiar environment.
BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, clinical trial management, clinical supply chain design, and associated optimization solutions. The company has been involved in the clinical development of many new medicines from early phase trials through final approval and operates advanced imaging core labs on two continents. They support worldwide eClinical and data management services from offices in the U.S., Europe, and Asia.
BioClinica’s OnPoint solutions are designed to help sponsors of clinical trials and CROs efficiently access, share, and analyze operational trial data by leveraging Microsoft® SharePoint standard collaboration and office automation tools. Users can interact with OnPoint via Microsoft Office applications, such as Outlook, Excel, and Word, through its integration with SharePoint. Interoperability is increased by a standards-based architecture supporting XML-based conventions and CDISC standards. BioClinica’s patent-pending data interchange technology eases the acquisition of operational data from multiple sources in real-time, facilitating integration with legacy and enterprise applications
.
CEO of BioClinica, Mark Weinstein, commented on the announcement, “We are proud to be selected to support Grünenthal’s clinical trial support needs, world-wide. This agreement demonstrates the results of our continuing commitment to deliver innovative technology solutions that help customers execute and manage their clinical trials with greater efficiency and speed.”
For additional information, visit the company’s website at www.bioclinica.com
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
